Cancer Stem Cells As Targets for DC-based Immunotherapy of Colorectal Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2018 Aug 15

PMID 30104575

Citations 19

Authors

Magdalena Szarynska

Agata Olejniczak

Jaroslaw Kobiela

Dariusz Laski

Zbigniew Sledzinski

Zbigniew Kmiec

Affiliations

Soon will be listed here.

Abstract

The therapy of colorectal cancer (CRC) patients is often unsuccessful because of the presence of cancer stem cells (CSCs) resistant to conventional approaches. Dendritic cells (DC)-based protocols are believed to effectively supplement CRC therapy. Our study was aimed to assess how the number and properties of CSCs isolated from tumor tissue of CRC patients will affect the biological characteristics of in vitro modified DCs. Similar procedures were conducted with the using of CRC HCT116 and HT29 cell lines. We found that the detailed configuration of CSC-like markers significantly influenced the maturation and activation of DCs after stimulation with cancer cells lysates or culture supernatants. This basic stimulatory effect was enhanced by LPS that is normally present in CRC CSCs niche. The increased number of CD29 and CD44 CSCs presented the opposite impact on treated DCs as showed by many significant correlations. The CD133 CSCs seemed to impair the functions of DCs. The more CD133 CSCs in tumor sample the lower number of activated DCs evidenced after stimulation. Moreover, our results showed superiority of the spherical culture model over the adherent one since spherical HCT116 and HT29 cells presented similar influence on DCs properties as CRC patients cancer cells. We concluded that the DCs features may depend directly on the properties of CSCs affected by progression status of tumor.

Citing Articles

Cellular Effects of Selected Unsymmetrical Bisacridines on the Multicellular Tumor Spheroids of HCT116 Colon and A549 Lung Cancer Cells in Comparison to Monolayer Cultures.

Kulesza J, Paluszkiewicz E, Augustin E Int J Mol Sci. 2023; 24(21).

PMID: 37958764 PMC: 10649579. DOI: 10.3390/ijms242115780.

Update on immune-based therapy strategies targeting cancer stem cells.

Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H Cancer Med. 2023; 12(18):18960-18980.

PMID: 37698048 PMC: 10557910. DOI: 10.1002/cam4.6520.

Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients.

Liu M, Zhou R, Zou W, Yang Z, Li Q, Chen Z Stem Cell Res Ther. 2023; 14(1):238.

PMID: 37674202 PMC: 10483786. DOI: 10.1186/s13287-023-03406-4.

Ecological niches for colorectal cancer stem cell survival and thrival.

Che J, Yu S Front Oncol. 2023; 13:1135364.

PMID: 37124519 PMC: 10134776. DOI: 10.3389/fonc.2023.1135364.

The Interplay between Integrins and Immune Cells as a Regulator in Cancer Immunology.

Zhang Q, Zhang S, Chen J, Xie Z Int J Mol Sci. 2023; 24(7).

PMID: 37047140 PMC: 10093897. DOI: 10.3390/ijms24076170.

References

Ahmed D, Eide P, Eilertsen I, Danielsen S, Eknaes M, Hektoen M . Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2:e71. PMC: 3816225. DOI: 10.1038/oncsis.2013.35. View

Kozovska Z, Gabrisova V, Kucerova L . Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 2014; 68(8):911-6. DOI: 10.1016/j.biopha.2014.10.019. View

Gandhi R, ONeill D, Bosch R, Chan E, Bucy R, Shopis J . A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009; 27(43):6088-94. PMC: 2820102. DOI: 10.1016/j.vaccine.2009.05.016. View

Pyzer A, Avigan D, Rosenblatt J . Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother. 2015; 10(11):3125-31. PMC: 4514037. DOI: 10.4161/21645515.2014.982993. View

Legitimo A, Consolini R, Failli A, Orsini G, Spisni R . Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother. 2014; 10(11):3224-35. PMC: 4514061. DOI: 10.4161/hv.29857. View

Munz C, Dao T, Ferlazzo G, de Cos M, Goodman K, Young J . Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2004; 105(1):266-73. DOI: 10.1182/blood-2004-06-2492. View

Shi J, Ikeda K, Fujii N, Kondo E, Shinagawa K, Ishimaru F . Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci. 2005; 96(2):127-33. PMC: 11160073. DOI: 10.1111/j.1349-7006.2005.00017.x. View

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

Lee C, Yu C, Wang B, Chang W . Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2015; 7(2):1215-26. PMC: 4811455. DOI: 10.18632/oncotarget.6261. View

10.

Amado N, Predes D, Moreno M, Carvalho I, Mendes F, Abreu J . Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies. Int J Mol Sci. 2014; 15(7):12094-106. PMC: 4139831. DOI: 10.3390/ijms150712094. View

11.

Cools N, Ponsaerts P, Van Tendeloo V, Berneman Z . Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007; 82(6):1365-74. DOI: 10.1189/jlb.0307166. View

12.

Gonzalez F, Gleisner A, Falcon-Beas F, Osorio F, Lopez M, Salazar-Onfray F . Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2015; 10(11):3261-9. PMC: 4514089. DOI: 10.4161/21645515.2014.982996. View

13.

Qureshi-Baig K, Ullmann P, Rodriguez F, Frasquilho S, Nazarov P, Haan S . What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue. PLoS One. 2016; 11(1):e0146052. PMC: 4706382. DOI: 10.1371/journal.pone.0146052. View

14.

Orsini G, Legitimo A, Failli A, Ferrari P, Nicolini A, Spisni R . Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease. Int J Mol Sci. 2013; 14(11):22022-41. PMC: 3856049. DOI: 10.3390/ijms141122022. View

15.

Sang M, Lian Y, Zhou X, Shan B . MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011; 29(47):8496-500. DOI: 10.1016/j.vaccine.2011.09.014. View

16.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

17.

Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H . Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001; 85(5):713-20. PMC: 2364114. DOI: 10.1054/bjoc.2001.1974. View

18.

Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R . Colon cancer stem cells. J Mol Med (Berl). 2009; 87(11):1097-104. DOI: 10.1007/s00109-009-0518-4. View

19.

Snyder K, Hughes M, Hedberg B, Brandon J, Hernaez D, Bergqvist P . Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res. 2015; 17:46. PMC: 4423095. DOI: 10.1186/s13058-015-0562-7. View

20.

Kim S, Yun C, Han S . Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. Cancer Lett. 2013; 335(2):278-88. DOI: 10.1016/j.canlet.2013.02.038. View